A Phase 1/2 Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combination With Pembrolizumab (KEYTRUDA) in Patients With Relapsed or Refractory Solid Tumors
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 18 Aug 2017
At a glance
- Drugs Birinapant (Primary) ; Pembrolizumab
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors TetraLogic Pharmaceuticals
- 18 Aug 2017 According to a Medivir AB media release, first patient has been enrolled.
- 25 Jul 2017 According to a Medivir AB media release, company expects to initiate the phase I portion of that study in the third quarter 2017.
- 18 Oct 2016 Planned End Date changed from 1 Mar 2019 to 1 Mar 2021.